Erenumab for Idiosyncratic Facial Pain

Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2021
Cargando información sobre las referencias
Eligible participants are randomized to receive either Erenumab or placebo bysubcutaneous injection once monthly for 6 months. Study duration is eight months whichincludes a 30 day screening/lead‐in period and 6 monthly treatment visits followed by afollow‐up visit one month following the last dose of study drug administration.Participants will be expected to score on a scale of 1 to 10 their symptoms of facialpain/pressure, nasal congestion, and rhinorrhea as well well as any rescue medicinestaken for pain each day via a mobile app.
Epistemonikos ID: c87ebf81eacef9b46f4c45d0da01e0ff5c6f3907
First added on: May 07, 2024